

- III. Claims 1-10, drawn to a polynucleotide encoding the polypeptide of SEQ ID NO:7, expression vector, host cell, and kit, classified in Class 435, subclasses 252.3, 320.1, and 810, and Class 536, subclass 23.6.
- IV. Claims 11, 12, and 15, drawn to a binding compound specific for the polypeptide of SEQ ID NO:2, and a kit, classified in Class 530, subclasses 350 and 387.1, and Class 536, subclass 23.6.
- V. Claims 11, 12, and 15, drawn to a binding compound specific for the polypeptide of SEQ ID NO:5, and a kit, classified in Class 530, subclasses 350 and 387.1, and Class 536, subclass 23.6.
- VI. Claims 11, 12, and 15, drawn to a binding compound specific for the polypeptide of SEQ ID NO:7, and a kit, classified in Class 530, subclasses 350 and 387.1, and Class 536, subclass 23.6.
- VII. Claims 13-14, drawn to a method of forming a complex with a binding protein specific for SEQ ID NO:2, classified in Class 530, subclass 350+.
- VIII. Claims 13-14, drawn to a method of forming a complex with a binding protein specific for SEQ ID NO:5, classified in Class 530, subclass 350+.
- IX. Claims 13-14, drawn to a method of forming a complex with a binding protein specific for SEQ ID NO:7, classified in Class 530, subclass 350+.
- X. Claims 16-18, drawn to a polypeptide comprising SEQ ID NO:2, classified in Class 530, subclasses 300 and 326.
- XI. Claims 16-18, drawn to a polypeptide comprising SEQ ID NO:5, classified in Class 530, subclasses 300 and 326.

- XII. Claims 16-18, drawn to a polypeptide comprising SEQ ID NO:7, classified in Class 530, subclasses 300 and 326.
- XIII. Claims 19-20, drawn to a method of modulating the physiology of a cell with a DC-STAMP antagonist, classified in Class 530, subclass 350+.
- XIV. Claims 19-20, drawn to a method of modulating the physiology of a cell with a DC-STAMP agonist, classified in Class 530, subclass 350+.
- XV. Claims 19-20, drawn to a method of modulating the physiology of a cell with a DSP-1 antagonist, classified in Class 530, subclass 350+.
- XVI. Claims 19-20, drawn to a method of modulating the physiology of a cell with a DSP-1 agonist, classified in Class 530, subclass 350+.

Applicants provisionally elect, with traverse, Group IV, drawn to a binding compound specific for the polypeptide of SEQ ID NO:7 and a kit, classified in Class 530, subclasses 350 and 387.1, and Class 536, subclass 23.6.

Applicants traverse the Restriction Requirement. Applicants request that the claims encompassed by Group IV (antibody to DC-STAMP) and Group XIII (method of using antibody to DC-STAMP) be rejoined and examined together.

Since the Examiner has not put forth a reason as to why it would be a serious burden to examine the claims in the above-identified groups together, Applicants contend that Groups IV and XIII should be examined together.

Applicants will address the issue of inventorship for the elected claims and amend inventorship appropriately if the elected restriction is made final.


Applicants reserve the right to file subsequent applications claiming the non-elected subject matter and do not waive any of their rights or abandon any non-elected subject matter. Since Applicants have fully and completely responded to

the Restriction Requirement and have made the required election, this application is now in order for early action.

Respectfully submitted,

Date: November 28, 2001

By:



Sheela Mohan-Peterson

Attorney for Applicants

Reg. No. 41,201

DNAX Research Institute
901 California Avenue
Palo Alto, California, 94304-1104
Tel. No. (650) 496-6400
Fax No.: (650) 496-1200